APOLLO success clears the path to an FDA decision
- Bitopertin achieved positive Phase 3 APOLLO results in October 2026.
- The company plans to resubmit its New Drug Application by the end of 2026.
- A major public offering extended the cash runway into 2030.
- The core risk shifts to the final FDA decision and a 2026 patent expiration.
Clinical risk removed, regulatory wait begins
Disc Medicine is moving closer to commercial reality. Its lead drug, bitopertin, was previously derailed by an FDA Complete Response Letter in early 2026. The agency demanded clear clinical proof that the drug improved sunlight tolerance for patients with rare blood disorders known as EPP and XLP.
The company delivered that proof in October 2026. The Phase 3 APOLLO trial met both primary endpoints, removing the biggest clinical overhang on the stock. Management now plans to resubmit the New Drug Application by the end of 2026, setting up a potential traditional FDA approval by mid-2027.
Disc capitalized on the positive data by raising nearly $486 million. This extends the cash runway into 2030, allowing the company to aggressively fund its earlier-stage pipeline, including DISC-0974 and DISC-3405.
The bull case is that bitopertin approval is now highly likely, transforming the company into a commercial operation. The bear case focuses on what happens after launch. The composition of matter patent for bitopertin expires in 2026, meaning investors must carefully watch the intellectual property strategy to see how long the commercial window will actually last.
Funded science, waiting for sales
Disc is a clinical-stage biotech company with no product revenue. The business is built entirely on drug discovery and clinical trials, funded by cash raised from stock sales and debt.
If the FDA approves bitopertin in mid-2027, Disc will begin transitioning into a commercial operation. Revenue would then come from direct product sales or regional partnerships. Until then, the company burns cash to run trials and prepare for launch.
The recent $486 million public offering removed near-term financing pressure. The company expects its current cash balance to fund operations into 2030. Expenses remain heavily weighted toward research and development.
Shots on blood biology
Bitopertin for EPP and XLP
The lead asset achieved positive Phase 3 APOLLO results in October 2026. Disc plans to resubmit the NDA by the end of 2026 for a potential mid-2027 approval.
Bitopertin for DBA
Disc is also testing bitopertin for Diamond-Blackfan Anemia in a Phase 2 trial. This is a smaller opportunity compared to the EPP and XLP markets.
DISC-0974 for anemia of myelofibrosis
This antibody is designed to lower hepcidin. Phase 2 RALLY-MF data showed promising responses, with more updates expected soon.
DISC-3405 for PV and SCD
This antibody targets TMPRSS6 to raise hepcidin. It is currently in Phase 2 testing for PV and Phase 1b for sickle cell disease.
One segment, expense-heavy
Disc reports one business segment: discovery and development of hematologic therapeutics. Because it has no product revenue, the mix below uses operating expenses, with R&D as the clear center of spending.
What could break
FDA asks for more work
High impact · Medium oddsEven with positive APOLLO data, the FDA could ask for extra analyses, longer follow-up, or a narrower label. That would delay revenue and raise costs.
Bitopertin patent overhang
High impact · High oddsThe composition of matter patent for bitopertin expires in 2026. Even if Disc wins approval in mid-2027, investors need to know what exclusivity protects the product after launch.
Pipeline fails to deliver
Medium impact · Medium oddsDisc is spending heavily on DISC-0974 and DISC-3405 to reduce its dependence on bitopertin. If those programs produce weak data, the company remains a single-product story.
In one breath
Does Disc Medicine have revenue?
No. The company has not generated product revenue yet. Future revenue depends on FDA approval for bitopertin and successful commercialization.
What were the APOLLO results?
In October 2026, Disc announced positive Phase 3 APOLLO results for bitopertin, meeting both primary endpoints. This clears the way for an NDA resubmission.
How long is the cash runway?
Following a massive $486 million public offering in October 2026, the company expects its cash balance to fund operations into 2030.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Disc Medicine, Inc. in Finn's Biotechnology industry ranking.

